CN112424200A - 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 - Google Patents

作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 Download PDF

Info

Publication number
CN112424200A
CN112424200A CN201980047285.5A CN201980047285A CN112424200A CN 112424200 A CN112424200 A CN 112424200A CN 201980047285 A CN201980047285 A CN 201980047285A CN 112424200 A CN112424200 A CN 112424200A
Authority
CN
China
Prior art keywords
amino
alkyl
radical
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980047285.5A
Other languages
English (en)
Other versions
CN112424200B (zh
Inventor
李继军
朱岩
王业柳
商现星
王虎庭
何伟男
严勤
孙颖慧
张凯
路畅
徐宏江
田心
杨玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202211301551.2A priority Critical patent/CN115716827A/zh
Publication of CN112424200A publication Critical patent/CN112424200A/zh
Application granted granted Critical
Publication of CN112424200B publication Critical patent/CN112424200B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本申请涉及式I所示的作为溴区结构域蛋白抑制剂的亚氨基砜类化合物及其药学上可接受的盐，并涉及所述化合物的制备方法、医药组合物及其医药用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980047285.5A 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 Active CN112424200B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211301551.2A CN115716827A (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810825047X 2018-07-25
CN201810825047 2018-07-25
CN2019104102736 2019-05-17
CN201910410273 2019-05-17
PCT/CN2019/097692 WO2020020288A1 (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211301551.2A Division CN115716827A (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Publications (2)

Publication Number Publication Date
CN112424200A true CN112424200A (zh) 2021-02-26
CN112424200B CN112424200B (zh) 2022-09-20

Family

ID=69180818

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211301551.2A Pending CN115716827A (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
CN201980047285.5A Active CN112424200B (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211301551.2A Pending CN115716827A (zh) 2018-07-25 2019-07-25 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Country Status (7)

Country Link
EP (1) EP3828183A4 (zh)
JP (1) JP7511557B2 (zh)
KR (1) KR20210038921A (zh)
CN (2) CN115716827A (zh)
AU (1) AU2019312393B2 (zh)
CA (1) CA3106733A1 (zh)
WO (1) WO2020020288A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
CA3133131A1 (en) * 2019-03-17 2020-09-24 Shanghai Ringene Biopharma Co., Ltd. Pyrrole amidopyridone compound, preparation method therefor and use thereof
AU2020299592A1 (en) * 2019-07-02 2022-02-17 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
EP4092027A4 (en) * 2020-01-19 2024-02-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTAL FORM AND SALT FORM OF A BROMODOMAIN PROTEIN INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF
GB202016977D0 (en) * 2020-10-26 2020-12-09 In4Derm Ltd Compounds
TW202311260A (zh) * 2021-05-12 2023-03-16 大陸商正大天晴藥業集團股份有限公司 含有亞磺醯亞胺基的atr抑制劑化合物
WO2022242697A1 (zh) * 2021-05-19 2022-11-24 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136435A (zh) * 2011-12-30 2014-11-05 艾伯维公司 溴结构域抑制剂
WO2017063959A1 (de) * 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
CN108069958A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
NZ586440A (en) 2008-06-26 2011-07-29 Resverlogix Corp Methods of preparing quinazolinone derivatives
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CN105518007A (zh) * 2013-06-28 2016-04-20 艾伯维公司 布罗莫结构域抑制剂
JP2017511801A (ja) 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
RU2741808C2 (ru) * 2016-04-15 2021-01-28 Эббви Инк. Ингибиторы бромодомена

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136435A (zh) * 2011-12-30 2014-11-05 艾伯维公司 溴结构域抑制剂
WO2017063959A1 (de) * 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
CN108069958A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
AU2019312393B2 (en) 2022-12-22
CN115716827A (zh) 2023-02-28
EP3828183A4 (en) 2022-03-09
KR20210038921A (ko) 2021-04-08
US20210300923A1 (en) 2021-09-30
WO2020020288A1 (zh) 2020-01-30
EP3828183A1 (en) 2021-06-02
AU2019312393A1 (en) 2021-03-18
JP2021533186A (ja) 2021-12-02
CN112424200B (zh) 2022-09-20
JP7511557B2 (ja) 2024-07-05
CA3106733A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CN112424200B (zh) 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
JP7026196B2 (ja) Ｒｅｔの阻害剤
US9980952B2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
KR101442585B1 (ko) 특정 치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
TW201927765A (zh) 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸
JP2021507896A (ja) Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
EP3728196A1 (en) Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
EP3119760A1 (en) Piperidine-dione derivatives
JP2021507895A (ja) Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸
JP2017522277A (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
JP2022500473A (ja) Ｌｐａアンタゴニストとしてのオキサビシクロ酸
CN112041029A (zh) 作为lpa拮抗剂的环己基酸吡唑唑类
WO2020257139A1 (en) Cyclobutyl carboxylic acids as lpa antagonists
CN115697974A (zh) 基于咪唑3-氧化物衍生物的acss2抑制剂和其使用方法
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
US12030880B2 (en) Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof
KR20080027914A (ko) 페닐피리딘 유도체, 이의 제조 및 약학 제제로서의 용도
BR112021010473A2 (pt) Composto de inibição de dock1 e uso
CN113412261A (zh) 苯并咪唑化合物、其制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Applicant after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

Applicant before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044332

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant